Company intelligence / Profile preview

Granite Bio

Ownership: Private
Development stage: Phase 1

Overview

GRT-001 is currently in Phase 1a testing in healthy volunteers and is expected to enter a Phase 1b trial in patients with inflammatory bowel disease later in 2025. In non-human primate studies, GRT-001 efficiently and dose-dependently depleted pro-inflammatory monocytes with good tolerability. GRT-002 is in preclinical development and expected to enter clinical trials in 2026[5][8].

Therapeutic areas: GastroenterologyDermatologyRheumatologyImmunology
Modalities: Therapeutic antibodies
Industry: Biotech

Drug pipeline

3 assets

GRT-002

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with Versant's Ridgeline Discovery Engine

Beyond the preview

Go deeper on Granite Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granite Bio.

Explore the full profile